- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Epigral's board approved Q1 financial results. Consolidated Revenue from Operations rose to ₹705.36 Cr (from ₹606.54 Cr YoY), but Profit After Tax declined to ₹99.74 Cr (from ₹160.69 Cr YoY). The company also formed a new wholly-owned subsidiary, Epigral Advanced Material, for chemical manufacturing.